Incyte, SmithKline Beecham Expand Collaborative Efforts with DB Partnership | GenomeWeb

PALO ALTO, Calif.--In the second major collaboration between the two companies announced this month, Incyte Pharmaceuticals here and SmithKline Beecham have entered into a multiyear partnership that will give SmithKline nonexclusive access to Incyte's PathoSeq microbial genome database in exchange for annual access fees and potential future royalties on sales of products developed with the information. The an nounce ment came approximately two weeks after the companies said they will form a joint venture, diaDexus, focused on data mining (see BioInform, September 15, page 1).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.